PNS173 Impact of COVID-19 on HTA Bodies and Pharmaceutical Company Pricing and Market Access Activities
Sign Up to like & getrecommendations! Published in 2020 at "Value in Health"
DOI: 10.1016/j.jval.2020.08.1617
Abstract: Objectives: Health technology assessment (HTA) bodies and pharmaceutical companies have been forced to react to an unprecedented level of disruption due to COVID-19 This study aims to determine the impact of the COVID-19 pandemic on… read more here.
Keywords: impact covid; hta bodies; company; impact ... See more keywords
OP30 Impact Of Patient Reported Outcomes Data On Health Technology Assessments Of Acute Myeloid Leukemia
Sign Up to like & getrecommendations! Published in 2019 at "International Journal of Technology Assessment in Health Care"
DOI: 10.1017/s0266462319001016
Abstract: Introduction Patient-reported outcomes (PRO) data are important in understanding patients’ experience of disease and treatment; however, PRO data are not universally collected or consistently included as part of a Health Technology Assessment (HTA) submission. Additionally,… read more here.
Keywords: hta bodies; health; evidence; pro data ... See more keywords
A call to action to harmonize patient-reported outcomes evidence requirements across key European HTA bodies in oncology.
Sign Up to like & getrecommendations! Published in 2022 at "Future oncology"
DOI: 10.2217/fon-2022-0374
Abstract: Patient-reported outcome (PRO) data are increasingly being included in Health Technology Assessment (HTA) submissions for oncology drugs. This study aims to provide differences in PRO evidence requirements in oncology across key HTA bodies and calls… read more here.
Keywords: evidence requirements; oncology; across key; patient reported ... See more keywords
Improving Interactions Between Health Technology Assessment Bodies and Regulatory Agencies: A Systematic Review and Cross-Sectional Survey on Processes, Progress, Outcomes, and Challenges
Sign Up to like & getrecommendations! Published in 2020 at "Frontiers in Medicine"
DOI: 10.3389/fmed.2020.582634
Abstract: The need to optimize drug development and facilitate faster access for patients has ignited discussions around the importance of improving interactions between health technology assessment (HTA) bodies and regulatory agencies. In this study, we conducted… read more here.
Keywords: regulatory agencies; hta bodies; systematic review; improving interactions ... See more keywords